Figure 6
Western blot analysis of ERMS/ARMS cells treated with MI-63. (A, B) Rhabdomyosarcoma cells with wild-type p53, RH36 and RH18, indicate increased p53, downstream targets, p21WAF1 and Bax, as well as cleaved caspase-3 and cleaved PARP, at 20, 30, and 40 h after treatment with 10 μ M of MI-63. (C, D) Rhabdomyosarcoma cells with mutated p53, RD2 and RH30, indicate no increase of p53, downstream target p21WAF1, cleaved caspase-3, and cleaved PARP at 24 and 36 h after treatment with 10 μM of MI-63.
